These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 8885123)
21. Phenotypic Assessment of Drug Metabolic Pathways and P-Glycoprotein in Patients Treated With Antidepressants in an Ambulatory Setting. Lloret-Linares C; Bosilkovska M; Daali Y; Gex-Fabry M; Heron K; Bancila V; Michalopoulos G; Perroud N; Richard-Lepouriel H; Aubry JM; Desmeules J; Besson M J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29570971 [TBL] [Abstract][Full Text] [Related]
22. Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion. Dash RP; Rais R; Srinivas NR Xenobiotica; 2018 Sep; 48(9):945-957. PubMed ID: 28876959 [TBL] [Abstract][Full Text] [Related]
23. Delayed bupropion cardiotoxicity associated with elevated serum concentrations of bupropion but not hydroxybupropion. Al-Abri SA; Orengo JP; Hayashi S; Thoren KL; Benowitz NL; Olson KR Clin Toxicol (Phila); 2013 Dec; 51(10):1230-4. PubMed ID: 24131328 [TBL] [Abstract][Full Text] [Related]
24. Venlafaxine serum levels and CYP2D6 genotype. Veefkind AH; Haffmans PM; Hoencamp E Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634 [TBL] [Abstract][Full Text] [Related]
25. Nefazodone pharmacokinetics in depressed children and adolescents. Findling RL; Preskorn SH; Marcus RN; Magnus RD; D'Amico F; Marathe P; Reed MD J Am Acad Child Adolesc Psychiatry; 2000 Aug; 39(8):1008-16. PubMed ID: 10939229 [TBL] [Abstract][Full Text] [Related]
26. Steady-state clinical pharmacokinetics of bupropion extended-release in youths. Daviss WB; Perel JM; Birmaher B; Rudolph GR; Melhem I; Axelson DA; Brent DA J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1503-9. PubMed ID: 17135996 [TBL] [Abstract][Full Text] [Related]
27. Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status. Gaebler AJ; Schneider KL; Stingl JC; Paulzen M Pharmacogenomics J; 2020 Dec; 20(6):840-844. PubMed ID: 32475982 [TBL] [Abstract][Full Text] [Related]
28. Metabolism of bupropion by carbonyl reductases in liver and intestine. Connarn JN; Zhang X; Babiskin A; Sun D Drug Metab Dispos; 2015 Jul; 43(7):1019-27. PubMed ID: 25904761 [TBL] [Abstract][Full Text] [Related]
29. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828 [TBL] [Abstract][Full Text] [Related]
30. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Zhu AZ; Cox LS; Nollen N; Faseru B; Okuyemi KS; Ahluwalia JS; Benowitz NL; Tyndale RF Clin Pharmacol Ther; 2012 Dec; 92(6):771-7. PubMed ID: 23149928 [TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106 [TBL] [Abstract][Full Text] [Related]
33. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553 [TBL] [Abstract][Full Text] [Related]
35. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model. Xue C; Zhang X; Cai W Pharmaceutics; 2017 Dec; 10(1):. PubMed ID: 29267251 [TBL] [Abstract][Full Text] [Related]
36. Seizure Related to the Split Extended-Release Bupropion Tablets in a Young Female Patient. Chou HY; Chang HA; Mao WC; Tai YM; Tzeng NS Am J Ther; 2019; 26(6):e777-e778. PubMed ID: 31436570 [No Abstract] [Full Text] [Related]
37. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. Laib AK; Brünen S; Pfeifer P; Vincent P; Hiemke C Ther Drug Monit; 2014 Aug; 36(4):473-9. PubMed ID: 24452068 [TBL] [Abstract][Full Text] [Related]
38. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. Hesse LM; Greenblatt DJ; von Moltke LL; Court MH J Clin Pharmacol; 2006 May; 46(5):567-76. PubMed ID: 16638740 [TBL] [Abstract][Full Text] [Related]
39. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936 [TBL] [Abstract][Full Text] [Related]
40. A possible bupropion and imipramine interaction. Shad MU; Preskorn SH J Clin Psychopharmacol; 1997 Apr; 17(2):118-9. PubMed ID: 10950476 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]